{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:16:31Z","timestamp":1771884991957,"version":"3.50.1"},"reference-count":17,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Monitoring cellular immune responses elicited in vaccinated individuals is highly complicated. Methods: 28 individuals participated during the vaccination process with 12 BNT162b2 mRNA (Pfizer) vaccine. Specific anti-RBD IgG using a classic ELISA was performed in days 10 and 20 (after one dose of the vaccine) and on day 35 (after two vaccine doses) in serum samples of all participants. In parallel, DTH (delayed-type hypersensitivity) Skin Test using S protein was performed before (11\/28) and after two doses (28\/28) of the vaccine. Results: 6\/28 individuals were considered positive for the specific anti-RBD IgG positive at day 10, whereas all 28 individuals were positive at day 20. Moreover, 28\/28 individuals increased the OD ratios at day 36 (2 doses). DTH cutaneous test was performed on 11\/28 participants at day 20 (1 dose) showing 8\/11 a positive reaction at 12 h. DTH of all participants was performed on day 36 (2 doses), showing 28\/28 positive reactions at 12 h. Conclusion: This report describes the first publication of the results obtained using an in vivo method, the classical DTH response to the Spike protein to assess T-cell immune responses in vaccinated individuals. This affordable and simple test would help to answer basic immunogenicity questions on large-scale population vaccine studies.<\/jats:p>","DOI":"10.3390\/vaccines9060575","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T23:07:03Z","timestamp":1622588823000},"page":"575","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals"],"prefix":"10.3390","volume":"9","author":[{"given":"Yvelise","family":"Barrios","sequence":"first","affiliation":[{"name":"Department of Immunology, Hospital Universitario de Canarias, 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Franco","sequence":"additional","affiliation":[{"name":"Department of Immunology, Hospital Universitario de Canarias, 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"S\u00e1nchez-Mach\u00edn","sequence":"additional","affiliation":[{"name":"Department of Allergy, Hospital Universitario de Canarias, 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Poza-Guedes","sequence":"additional","affiliation":[{"name":"Department of Allergy, Hospital Universitario de Canarias, 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruperto","family":"Gonz\u00e1lez-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Allergy, Hospital Universitario de Canarias, 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0469-800X","authenticated-orcid":false,"given":"Victor","family":"Matheu","sequence":"additional","affiliation":[{"name":"Department of Allergy, Hospital Universitario de Canarias, 38320 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Schwarzkopf, S., Krawczyk, A., Knop, D., Klump, H., Heinold, A., Heinemann, F.M., Th\u00fcmmler, L., Temme, C., Breyer, M., and Witzke, O. (2021). Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG. Emerg. Infect. Dis., 27.","DOI":"10.3201\/eid2701.203772"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41590-021-00902-8","article-title":"Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection","volume":"22","author":"Zuo","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Doria-Rose, N., Suthar, M.S., Makowski, M., O\u2019Connell, S., McDermott, A.B., Flach, B., Ledgerwood, J.E., Mascola, J.R., Graham, B.S., and Lin, B.C. (2021). Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N. Engl. J. Med.","DOI":"10.1056\/NEJMc2103916"},{"key":"ref_4","first-page":"1663","article-title":"COVID-19 vaccines: Comparison of biological, pharmacological charac-teristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., and Rosenfeld, A.M. (2021). Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination. Sci. Immunol., 6.","DOI":"10.1126\/sciimmunol.abi6950"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Barrios, Y., Franco, A., Sanchez-Machin, I., Poza-Guedes, P., Gonzalez-Perez, R., and Matheu, V. (2021). A novel application of delayed-type hipersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals. Clin. Immunol., 226.","DOI":"10.1016\/j.clim.2021.108730"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.cmi.2020.06.024","article-title":"Validation of a commercially available SARS-CoV-2 serological immunoassay","volume":"26","author":"Meyer","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18176\/jiaci.0267","article-title":"Safety and Quality Recommendations in Allergy Medicine (Spanish acronym, RESCAL)","volume":"28","author":"Vidal","year":"2018","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Badaro, R., Machado, B.A.S., Duthie, M.S., Araujo-Neto, C.A., Pedral-Sampaio, D., Nakatani, M., and Reed, S.G. (2020). The single recombinant M. tuberculosis protein DPPD provides enhanced performance of skin testing among HIV-infected tuberculosis patients. Amb Express, 10.","DOI":"10.1186\/s13568-020-01068-6"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Borah, P., Deb, P.K., Al-Shar\u2019I, N.A., Dahabiyeh, L.A., Venugopala, K.N., Singh, V., Shinu, P., Hussain, S., Deka, S., and Chandrasekaran, B. (2021). Perspectives on RNA Vaccine Candidates for COVID-19. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.635245"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0008-8749(82)90036-3","article-title":"Immunohistological analysis of delayed-type hypersensitivity in man","volume":"74","author":"Poulter","year":"1982","journal-title":"Cell. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/0378-6323.29351","article-title":"Intradermal tests in dermatology-I: Tests for infectious diseases","volume":"72","author":"Nagar","year":"2006","journal-title":"Indian J. Derm. Venereol. Leprol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115148","DOI":"10.1016\/j.diagmicrobio.2020.115148","article-title":"COVID-19: Is there a role for Western blots and skin testing for determining immunity and development of a vaccine?","volume":"98","author":"Pavia","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","article-title":"Lessons for COVID-19 Immunity from Other Coronavirus Infections","volume":"53","author":"Sariol","year":"2020","journal-title":"J. Immun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: Immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2014.03.008","article-title":"Immunosenescence: Influenza vaccination and the elderly","volume":"29","author":"Haq","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/6\/575\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:45Z","timestamp":1760162985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/6\/575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["vaccines9060575"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9060575","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}